BR112017009807A2 - métodos e formulações para tratamento de doenças oculares vasculares - Google Patents
métodos e formulações para tratamento de doenças oculares vascularesInfo
- Publication number
- BR112017009807A2 BR112017009807A2 BR112017009807A BR112017009807A BR112017009807A2 BR 112017009807 A2 BR112017009807 A2 BR 112017009807A2 BR 112017009807 A BR112017009807 A BR 112017009807A BR 112017009807 A BR112017009807 A BR 112017009807A BR 112017009807 A2 BR112017009807 A2 BR 112017009807A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- formulations
- eye diseases
- treating vascular
- vascular eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Abstract
a presente invenção fornece métodos para o tratamento, prevenção ou redução da gravidade de uma doença ocular. os métodos da presente invenção compreendem administrar em um indivíduo que precisa do mesmo uma composição terapêutica que compreende um inibidor de angiopoietina-2 (ang-2), como um anticorpo anti-ang-2, em combinação com um antagonista de fator de crescimento endotelial vascular (vegf) (por exemplo, aflibercept).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462084003P | 2014-11-25 | 2014-11-25 | |
US201562147232P | 2015-04-14 | 2015-04-14 | |
US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
PCT/US2015/061543 WO2016085750A1 (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017009807A2 true BR112017009807A2 (pt) | 2018-02-27 |
Family
ID=56009149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017009807A BR112017009807A2 (pt) | 2014-11-25 | 2015-11-19 | métodos e formulações para tratamento de doenças oculares vasculares |
Country Status (18)
Country | Link |
---|---|
US (3) | US20160144025A1 (pt) |
EP (1) | EP3224278A4 (pt) |
JP (2) | JP2017536414A (pt) |
KR (1) | KR20170087950A (pt) |
CN (1) | CN107001457A (pt) |
AU (1) | AU2015353838A1 (pt) |
BR (1) | BR112017009807A2 (pt) |
CA (1) | CA2968522A1 (pt) |
CL (1) | CL2017001188A1 (pt) |
CO (1) | CO2017004715A2 (pt) |
EA (1) | EA201791168A1 (pt) |
IL (1) | IL252159B (pt) |
MA (2) | MA41028A (pt) |
MX (1) | MX2017006129A (pt) |
PE (1) | PE20170900A1 (pt) |
PH (1) | PH12017500834A1 (pt) |
SG (1) | SG11201703609UA (pt) |
WO (1) | WO2016085750A1 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
PL2371865T3 (pl) | 2006-04-07 | 2018-02-28 | Aerpio Therapeutics, Inc. | Przeciwciała wiążące ludzką białkową fosfatazę tyrozynową beta (HPTP-β) oraz ich zastosowania |
SI2364691T1 (sl) | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
SG172313A1 (en) | 2009-07-06 | 2011-07-28 | Akebia Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
CA2998673C (en) | 2015-09-23 | 2023-12-12 | Aerpio Therapeutics, Inc. | Methods of treating intraocular pressure with activators of tie-2 |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
US20190300607A1 (en) * | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
CN110709104A (zh) * | 2017-05-06 | 2020-01-17 | 瑞泽恩制药公司 | 用aplnr拮抗剂和vegf抑制剂治疗眼部病症的方法 |
CN111132695A (zh) * | 2017-08-18 | 2020-05-08 | 里珍纳龙药品有限公司 | 分析样品基质中蛋白变异体的成像毛细管等电聚焦 |
KR102494021B1 (ko) * | 2017-12-22 | 2023-02-06 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
US11667702B2 (en) | 2018-03-08 | 2023-06-06 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术(上海)有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
US11518819B2 (en) * | 2018-08-17 | 2022-12-06 | Trican Biotechnology Co., Ltd | Anti-angiogenesis fusion protein and uses thereof |
CN109598628B (zh) * | 2018-11-30 | 2022-09-20 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
US11945859B2 (en) | 2018-12-18 | 2024-04-02 | Novartis Ag | Protein solution formulation containing high concentration of an anti-VEGF antibody |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
JP2022530657A (ja) | 2019-04-29 | 2022-06-30 | アイポイント ファーマシューティカルズ, インコーポレイテッド | シュレム管を標的とするTie-2活性化物質 |
CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
AU2020393842A1 (en) | 2019-11-25 | 2022-06-16 | The Regents Of The University Of California | Long-acting VEGF inhibitors for intraocular neovascularization |
CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
WO2021259200A1 (zh) * | 2020-06-22 | 2021-12-30 | 信达生物制药(苏州)有限公司 | 抗ang-2抗体及其用途 |
KR20220013343A (ko) * | 2020-07-24 | 2022-02-04 | (주) 팬젠 | 안과용 액상 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
SI2364691T1 (sl) * | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
MX2011012691A (es) * | 2009-05-28 | 2012-04-19 | Glaxo Group Ltd | Combinacion de un antagonista de tnf-alfa y un antagonista de vegf para utilizarse en el tratamiento o en la prevencion de enfermedades de los ojos. |
US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
KR20200077622A (ko) * | 2011-01-13 | 2020-06-30 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
BR112014017882A2 (pt) * | 2012-01-23 | 2017-06-27 | Regeneron Pharma | formulações estabilizadas contendo anticorpos anti-ang-2 |
LT3495387T (lt) * | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
EP3851454A1 (en) * | 2012-12-05 | 2021-07-21 | Novartis AG | Compositions and methods for antibodies targeting epo |
JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
BR112016000282A2 (pt) * | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
DE112014005975T5 (de) * | 2013-12-17 | 2016-09-15 | Kymab Limited | Menschliche Ziele |
US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko unknown
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en active Application Filing
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190117767A1 (en) | 2019-04-25 |
PE20170900A1 (es) | 2017-07-12 |
JP2021046431A (ja) | 2021-03-25 |
JP2017536414A (ja) | 2017-12-07 |
CL2017001188A1 (es) | 2017-11-24 |
WO2016085750A1 (en) | 2016-06-02 |
US20160144025A1 (en) | 2016-05-26 |
MA40306A1 (fr) | 2019-03-29 |
US11071780B2 (en) | 2021-07-27 |
IL252159B (en) | 2021-03-25 |
KR20170087950A (ko) | 2017-07-31 |
EP3224278A4 (en) | 2018-07-11 |
SG11201703609UA (en) | 2017-06-29 |
MX2017006129A (es) | 2018-04-10 |
US20170080086A1 (en) | 2017-03-23 |
EP3224278A1 (en) | 2017-10-04 |
IL252159A0 (en) | 2017-07-31 |
CA2968522A1 (en) | 2016-06-02 |
AU2015353838A1 (en) | 2017-06-08 |
EA201791168A1 (ru) | 2017-09-29 |
PH12017500834A1 (en) | 2017-10-30 |
CO2017004715A2 (es) | 2017-09-20 |
MA41028A (fr) | 2017-10-03 |
CN107001457A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
CO6551721A2 (es) | Moduladores de cinasa novedosos | |
WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
CL2015002485A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares | |
BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
BR112016029334A2 (pt) | produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos | |
BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
AR091237A1 (es) | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) | |
BR112016025470A2 (pt) | ?hdl terapêutico? | |
BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
BR112015030385A2 (pt) | inibidores de pi3 delta e gama quinase seletivos duplos | |
BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
BR112017015789A2 (pt) | vacina de vírus da influenza suína bivalente | |
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
BR112018015453A2 (pt) | vírus atenuado da bronquite infecciosa | |
ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
BR112017005828A2 (pt) | métodos para tratar ou prevenir uma infecção respiratória, copd e uma exacerbação de copd e para selecionar um inibidor de sinalização notch 3 e/ou notch4, usp de um inibidor de sinalização de notch 3 e/ou notch 4, inibidor de sinalização de notch 3 e/ou notch 4, e, composição farmacêutica. | |
MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2697 DE 13/09/2022. |